Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2009

View Archived Issues

New PARP-1 inhibitors with anticancer activity discovered at AstraZeneca

Novel mGluR2 ligands for schizophrenia and other disorders disclosed by Pfizer researchers

New MAP kinase inhibitors useful for treating asthma reported in recent AstraZeneca patent

Recent Merck Frosst patent claims new GPR105 antagonists for type 2 diabetes and obesity

Novel glucokinase activators jointly reported by Nissan Chemical and Taisho

New deuterium-enriched clopidogrel analogues under development at Protia

Microbicide Trials Network releases BufferGel and PRO-2000/5 trial data

Viralytics initiates head and neck cancer trial with Cavatak

Winston presents topline civamide patch results

Q3 highlights at Mitsubishi Tanabe Pharma

Arete starts phase IIa AR-9281 trial in type 2 diabetes

Capstone commences dosing in phase II AZX-100 trial in dermal scarring

SPI-452 inhibits CYP3A in vitro, increases protease inhibitor exposure in humans

Aeolus initiates studies of AEOL-10150 as a countermeasure to mustard gas exposure

HIV pharmaco-enhancer GS-9350 inhibits CYP3A and has no antiviral effects

Cell and IDIS sign collaborative agreement for pixantrone named-patient program

Dyax and Fovea sign exclusive E.U. license agreement for DX-88 in ophthalmic indications

FDA accepts Enzon's IND to initiate phase I study of its survivin antagonist

Cougar reaches agreement with FDA under SPA for phase III clinical trial of CB-7630

Synta treats first patient in clinical trial of elesclomol for solid tumors

DiaMedica completes treatment in phase IIa clinical trial of DM-99 in type 2 diabetes

Merrion completes patient enrolment in phase IIb study of Orazol

Enzon discontinues rhMBL development

ConjuChem data confirms PC-DAC lowers glucose in diabetes trials

Vivus initiates second pivotal phase III avanafil trial for erectile dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...